Testosterone topical - AbbVie/Besins

Drug Profile

Testosterone topical - AbbVie/Besins

Alternative Names: 1% Testosterone gel (AndroGel) - AbbVie; 1.62% Testosterone gel - Solvay; AndroGel; AndroGel PD; Testogel; Testosterone topical - Abbott

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Besins International; Unimed Pharmaceuticals
  • Developer AbbVie; Besins Healthcare; Solvay
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Androgen receptor agonists; Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypogonadism
  • Discontinued Growth disorders

Most Recent Events

  • 04 Feb 2016 No recent reports on development identified - Phase-III for Hypogonadism in China (Topical)
  • 02 Sep 2015 First Generic equivalent available in USA for Hypogonadism
  • 23 Jan 2015 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top